A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine

Robert A. Smith; George J. Klarmann; Kirsten M. Stray; Uta K. Von Schwedler; Raymond F. Schinazi; Bradley D. Preston; Thomas W. North

A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine

Robert A. Smith, George J. Klarmann, Kirsten M. Stray, Uta K. Von Schwedler, Raymond F. Schinazi, Bradley D. Preston, Thomas W. North

Molecular Biosciences

Research output: Contribution to journal › Article

9 Scopus citations

Abstract

A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'- deoxythymidine (AZT) and to (R)-9-(2-phosphonyimethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.

Original language	English (US)
Pages (from-to)	2077-2080
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	43
Issue number	8
State	Published - Aug 1999

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

Fingerprint Dive into the research topics of 'A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine'. Together they form a unique fingerprint.

Cite this

Smith, R. A., Klarmann, G. J., Stray, K. M., Von Schwedler, U. K., Schinazi, R. F., Preston, B. D., & North, T. W. (1999). A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine. Antimicrobial Agents and Chemotherapy, 43(8), 2077-2080.

A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine. / Smith, Robert A.; Klarmann, George J.; Stray, Kirsten M.; Von Schwedler, Uta K.; Schinazi, Raymond F.; Preston, Bradley D.; North, Thomas W.

In: Antimicrobial Agents and Chemotherapy, Vol. 43, No. 8, 08.1999, p. 2077-2080.

Research output: Contribution to journal › Article

Smith, Robert A. ; Klarmann, George J. ; Stray, Kirsten M. ; Von Schwedler, Uta K. ; Schinazi, Raymond F. ; Preston, Bradley D. ; North, Thomas W. / A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine. In: Antimicrobial Agents and Chemotherapy. 1999 ; Vol. 43, No. 8. pp. 2077-2080.

@article{22336bee0a214aef8ba217118e5e0764,

title = "A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine",

abstract = "A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'- deoxythymidine (AZT) and to (R)-9-(2-phosphonyimethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.",

author = "Smith, {Robert A.} and Klarmann, {George J.} and Stray, {Kirsten M.} and {Von Schwedler}, {Uta K.} and Schinazi, {Raymond F.} and Preston, {Bradley D.} and North, {Thomas W.}",

year = "1999",

month = aug,

language = "English (US)",

volume = "43",

pages = "2077--2080",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine

AU - Smith, Robert A.

AU - Klarmann, George J.

AU - Stray, Kirsten M.

AU - Von Schwedler, Uta K.

AU - Schinazi, Raymond F.

AU - Preston, Bradley D.

AU - North, Thomas W.

PY - 1999/8

Y1 - 1999/8

N2 - A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'- deoxythymidine (AZT) and to (R)-9-(2-phosphonyimethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.

AB - A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'- deoxythymidine (AZT) and to (R)-9-(2-phosphonyimethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.

UR - http://www.scopus.com/inward/record.url?scp=0032817243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032817243&partnerID=8YFLogxK

M3 - Article

C2 - 10428942

AN - SCOPUS:0032817243

VL - 43

SP - 2077

EP - 2080

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -